MAP2K7 and melanoma: After short‐term response, most melanoma cells that develop secondary resistance to MEK inhibitor underwent loss of antigen presentation [500], experienced epithelial‐to‐mesenchymal transition [501], and remodeled extracellular matrix, which was associated with increased the number of Tregs and M2‐TAMs and led to innate or adaptive resistance of ICIs [502].